Dimitra Kiritsi,Kathrin Dieter,Elke Niebergall-Roth,Silvia Fluhr,Cristina Daniele,Jasmina Esterlechner,Samar Sadeghi,Seda Ballikaya,Leoni Erdinger,Franziska Schauer,Stella Gewert,Martin Laimer,Johann W. Bauer,Alain Hovnanian,Giovanna Zambruno,May El Hachem,Emmanuelle Bourrat,Maria Papanikolaou,Gabriela Petrof,Sophie Kitzmüller,Christen L. Ebens,Markus H. Frank,Natasha Y. Frank,Christoph Ganss,Anna E. Martinez,John A. McGrath,Jakub Tolar,Mark A. Kluth

Abstract:BACKGROUNDRecessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating, and life-threatening inherited skin fragility disorder that comes about due to a lack of functional type VII collagen, for which no effective therapy exists. ABCB5+ dermal mesenchymal stem cells (ABCB5+ MSCs) possess immunomodulatory, inflammation-dampening, and tissue-healing capacities. In a Col7a1-/- mouse model of RDEB, treatment with ABCB5+ MSCs markedly extended the animals' lifespans.METHODSIn this international, multicentric, single-arm, phase I/IIa clinical trial, 16 patients (aged 4-36 years) enrolled into 4 age cohorts received 3 i.v. infusions of 2 × 106 ABCB5+ MSCs/kg on days 0, 17, and 35. Patients were followed up for 12 weeks regarding efficacy and 12 months regarding safety.RESULTSAt 12 weeks, statistically significant median (IQR) reductions in the Epidermolysis Bullosa Disease Activity and Scarring Index activity (EBDASI activity) score of 13.0% (2.9%-30%; P = 0.049) and the Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa clinician (iscorEB‑c) score of 18.2% (1.9%-39.8%; P = 0.037) were observed. Reductions in itch and pain numerical rating scale scores were greatest on day 35, amounting to 37.5% (0.0%-42.9%; P = 0.033) and 25.0% (-8.4% to 46.4%; P = 0.168), respectively. Three adverse events were considered related to the cell product: 1 mild lymphadenopathy and 2 hypersensitivity reactions. The latter 2 were serious but resolved without sequelae shortly after withdrawal of treatment.CONCLUSIONThis trial demonstrates good tolerability, manageable safety, and potential efficacy of i.v. ABCB5+ MSCs as a readily available disease-modifying therapy for RDEB and provides a rationale for further clinical evaluation.TRIAL REGISTRATIONClinicaltrials.gov NCT03529877; EudraCT 2018-001009-98.FUNDINGThe trial was sponsored by RHEACELL GmbH & Co. KG. Contributions by NYF and MHF to this work were supported by the NIH/National Eye Institute (NEI) grants RO1EY025794 and R24EY028767.

Rescue of the mucocutaneous manifestations by human cord blood derived nonhematopoietic stem cells in a mouse model of recessive dystrophic epidermolysis bullosa

Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients

398 A Simple, Efficient Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Histological and molecular restoration of type VII collagen in Recessive dystrophic epidermolysis bullosa mouse skin by topical injection of keratinocyte-like cells differentiated from human adipose-derived mesenchymal stromal cells

CRISPR-Cas9-based Non-Viral Gene Editing Therapy for Topical Treatment of Recessive Dystrophic Epidermolysis Bullosa

836 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using a Highly Branched Poly(β-Amino Ester) Polymer (HPAE-EB)

455 Non-viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa: Hyper Branched Aminated Polyesters Mediated Minicircle DNA Delivery

Development of Minicircle Vectors Encoding COL7A1 Gene with Human Promoters for Non-Viral Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa.

Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa

834 CRISPR/Cas9 Based COL7A1 Genomic Editing in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Via Non-Viral Polymer Delivery System

Efficient and Robust Highly Branched Poly(β-amino Ester)/minicircle COL7A1 Polymeric Nanoparticles for Gene Delivery to Recessive Dystrophic Epidermolysis Bullosa Keratinocytes

Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa

Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.

200 A Comparison of Minicircle Vectors Expressing COL7A1 under the Control of Human Promoters for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa

901 Non-viral Gene Editing Therapy for Recessive Dystrophic Epidermolysis Bullosa: CRISPR/Cas9 Mediated COL7A1 Exon 80 Deletion Strategy

Generation of the Induced Pluripotent Stem Cell Line (Zsphari001-A) from a Patient with Recessive Dystrophic Epidermolysis Bullosa Carrying Compound Heterozygous Mutation in the COL7A1 Gene.

Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa

CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells

Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: a scoping review of the literature and conclusions for future clinical research

New options to manage epidermolysis bullosa